Sugi Predict

Sugi Predict / Compounds / SCHEMBL6800632

SCHEMBL6800632

SCHEMBL6800632

ClCC=CCC1CCCCCN1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HTR1A P08908 2/20 0.43
▸ HTR2A P28223 2/20 0.43
▸ KCNH2 Q12809 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MLNR O43193 1/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ EGFR P00533 1/20 0.43
▸ FYN P06241 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ CHRM4 P08173 1/20 0.43
▸ CHRM5 P08912 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ ADORA3 P0DMS8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15901489 0.81 CYP2D6 (0.43) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL27961055 0.78 CYP2D6 (0.44) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL15901236 0.78 CYP2D6 (0.44) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL28589905 0.76 FDPS (0.42) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL27264900 0.76 CYP2D6 (0.42) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL9112086 0.76 CYP2D6 (0.42) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL16767662 0.76 POLB (0.40) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL7059821 0.74 CYP2D6 (0.52) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL816943 0.73 FDPS (0.40) CYP2D6MEN1LMNATP53KMT2A
SCHEMBL29779787 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6482944-B2 BY DIRECT REACTION OF AN AMINE WITH AN ALPHA, GAMMA-DIHALOALKANE OR AN ALPHA, GAMMA-DIHALOALKENE; TERTIARY AMINOALKYLORGANOMETALLICS CAN BE MADE BY THEN REACTING THE TERT HALOALKYLAMINES WITH AN ALKALI METALS FMC CORPORATION 2002-11-19 — — US claimed
US-20010023305-A1 Processes for preparing haloamines and tertiary aminoalkylorganometallic compounds FMC CORPORATION 2001-09-20 — — US claimed
US-6717014-B1 REACTING AMINES WITH ALPHA-, OMEGA - DIHALOALKANES OR ALKENES; LOW COST; SAFE FMC CORPORATION 2004-04-06 — — US disclosed
US-6482944-B2 BY DIRECT REACTION OF AN AMINE WITH AN ALPHA, GAMMA-DIHALOALKANE OR AN ALPHA, GAMMA-DIHALOALKENE; TERTIARY AMINOALKYLORGANOMETALLICS CAN BE MADE BY THEN REACTING THE TERT HALOALKYLAMINES WITH AN ALKALI METALS FMC CORPORATION 2002-11-19 — — US disclosed
US-20010023305-A1 Processes for preparing haloamines and tertiary aminoalkylorganometallic compounds FMC CORPORATION 2001-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023305-A1 Processes for preparing haloamines and tertiary aminoalkylorganometallic compounds HDHD5, DDC, DDT CYP2D6 710/4885MEN1 1870/4885LMNA 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.